In 2019 a biopsy of my prostate revealed GG4 tumor. The Decipher score was 0.89 and a Foundation One test showed...

Understanding Your Complex Prostate Cancer Situation

Thank you for sharing such detailed information about your journey. Your case illustrates why advanced prostate cancer requires careful, individualized interpretation—and why the educational resources from the Cancer Patient Lab webinars are particularly relevant to your situation.

What [facility removed]al Picture Shows

Let me break down what's happening and what doctors typically consider in situations like yours:

The Biomarker Context (2019)

Your original biopsy findings told an important story:

• Gleason Grade 4 (GG4): Indicates more aggressive tumor biology
• Decipher score of 0.89: This genomic test predicts higher risk of metastasis and treatment resistance
• PTEN and TP53 mutations: These are "driver mutations"—genetic changes that fuel cancer growth. TP53 mutations particularly suggest more aggressive biology and potential resistance to standard therapies

According to the NCCN Guidelines for Prostate Cancer, these findings together indicated you had high-risk disease requiring aggressive initial treatment, which you received (radiation, brachytherapy, and 18 months of ADT).

The Current Puzzle: PSA vs. Imaging

Here's where your situation becomes clinically interesting and why it requires your oncologist's expertise:

What doctors typically observe:

• PSA response (0.03): Suggests your cancer cells are responding to your current treatment (abiraterone + docetaxel)
• Persistent PET uptake despite low PSA: This is the puzzle. It can mean several things:
  • Some metastatic sites may have cells that produce less PSA but still have metabolic activity
  • Inflammation or benign processes can show uptake
  • Some tumor cells may be in a "dormant" state metabolically
  • Different metastatic sites may respond differently to treatment

According to the American Cancer Society and ASCO Guidelines, this discordance between PSA response and imaging findings is recognized as a real clinical challenge in advanced prostate cancer. It's not uncommon, but it requires careful interpretation.

The Spatial/Microenvironment Perspective

This is where the BostonGene Tumor Portrait research discussed in the Cancer Patient Lab webinars becomes relevant to your thinking. As Michael Hensley and Katerina Postovalova explained in their webinar on "Predicting Immunotherapy Response," understanding the tumor microenvironment—the immune cells and stromal components surrounding your cancer—can help explain why some sites respond differently than others.

The webinar noted that:

• Different regions of metastatic disease can have very different immune compositions
• Some sites may be "inflamed" (immune-rich) while others are "immune-excluded" or "immune deserts"
• This spatial organization affects how treatments work and how tumors evolve

In your case, the varying PET uptake across different metastatic sites might reflect these different microenvironments—some sites responding better to your current therapy than others.

What [facility removed]ally

The encouraging signs:

• Your PSA response is real and meaningful
• You've tolerated multiple lines of therapy
• Some metastatic sites are showing reduced uptake over time

The complexity:

• Persistent uptake in some sites despite PSA response suggests incomplete control
• Your tumor's genetic profile (TP53, PTEN mutations) indicates it may develop resistance over time
• The discordance between PSA and imaging requires ongoing monitoring and interpretation

Critical Questions to Ask Your Oncology Team

Based on your situation, here are specific questions that could help you understand your treatment trajectory:

1. On the imaging discordance: "My PSA is very low, but some metastatic sites still show uptake. What does this tell you about which sites are responding well versus which ones concern you most? Are there sites you're watching more closely?"

2. On treatment strategy: "Given that I've now had multiple treatments (ADT, abiraterone, docetaxel), what's your thinking about next steps if PSA rises again or if imaging shows progression? Are there other options we should be discussing now?"

3. On tumor biology: "My original tumor had PTEN and TP53 mutations. Do you think these mutations are influencing how my cancer is responding now? Should we consider repeat molecular testing to see if the tumor biology has changed?"

4. On monitoring approach: "How are you weighing PSA versus imaging in making treatment decisions? If they continue to diverge, how will that affect your recommendations?"

5. On emerging options: "Are there clinical trials or newer treatments (like immunotherapy combinations, newer hormonal agents, or targeted therapies) that might be appropriate given my tumor's genetic profile and current response pattern?"

6. On tumor microenvironment: "Would it be helpful to do additional molecular profiling of my current metastatic disease to understand the tumor microenvironment and immune composition? Could that inform treatment decisions?"

Why This Matters

As the Cancer Patient Lab webinars emphasize, particularly in the discussion of precision oncology and the Advanced Cancer Navigator, every patient's tumor is unique. Your specific combination of:

• Original aggressive biology (GG4, high Decipher score)
• Specific mutations (PTEN, TP53)
• Current treatment response pattern (PSA vs. imaging discordance)
• Multiple metastatic sites with different responses

...requires your oncologist to synthesize all this information into a personalized strategy. The webinars stress that "there are far more rational regimens than can be tested in clinical trials," meaning your doctor's interpretation of YOUR specific situation is crucial.

Moving Forward

Your engagement with understanding your disease—which you're clearly demonstrating—is valuable. The Cancer Patient Lab resources emphasize that engaged patients get better outcomes. Continue to:

• Track your PSA and imaging results over time
• Ask about the reasoning behind treatment decisions
• Discuss what "success" looks like given your situation
• Consider whether additional molecular profiling might inform decisions
• Explore whether clinical trials might be appropriate for your specific tumor profile

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Sources cited: NCCN Guidelines for Prostate Cancer; American Cancer Society Prostate Cancer Information; ASCO Guidelines; Cancer Patient Lab Webinars on BostonGene Tumor Portrait and Advanced Cancer Navigator